PF-06747775 Clinical Trials (2026): 1 Studies for Non-Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 PF-06747775 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Non-Small Cell Lung Cancer) and 65 total planned enrollment. Most recent activity: NCT02349633 (May 2020).
PF-06747775 clinical trials at a glance: phase × recruitment status
| Phase | terminated | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Terminated and withdrawn PF-06747775 trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT02349633terminatedStudy For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
All PF-06747775 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | P1/P2 | terminated | 65 | Pfizer | May 2015 |
PF-06747775 clinical trials: frequently asked questions
- How many PF-06747775 clinical trials are there?
- 1 PF-06747775 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are PF-06747775 clinical trials recruiting in 2026?
- No active PF-06747775 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is PF-06747775 being studied for?
- PF-06747775 is being studied for Non-Small Cell Lung Cancer. The trials are grouped by indication on this page.
- Who sponsors PF-06747775 clinical trials?
- The lead sponsor across the most PF-06747775 trials is Pfizer. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming PF-06747775as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: